NCT07480733招募中2 期
A Phase II Clinical Study Evaluating the Safety, Tolerability,Pharmacokinetics, and Preliminary Efficacy of JS212 andJS213 as Monotherapy and in Combination in Patients Withadvanced Malignant Solid Tumors
Shanghai Junshi Bioscience Co., Ltd.1 个研究点 分布在 1 个国家目标入组 410 人开始时间: 2026年4月23日最近更新:
干预措施
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 410
- 试验地点
- 1
- 主要终点
- ORR
研究概览
简要总结
This is a multicenter, open-label Phase II clinical study. The primary objective is to evaluate the investigator-assessed objective response rate of JS212 and JS213 as monotherapy and in combination regimens in patients with advanced solid tumors. This study aims to explore the safety, tolerability, and preliminary efficacy of JS212, JS213, as well as JS212 in combination with JS213, toripalimab, and JS207.
详细描述
This study is a Phase II clinical trial designed to evaluate the safety, tolerability, PK characteristics, and preliminary efficacy of JS212 and JS213 as monotherapy and in combination therapy in patients with advanced malignant solid tumors. This study plans to conduct 5 treatment cohorts:
Cohort 1: JS212 Cohort 2: JS213 Cohort 3: JS212 + JS213 Cohort 4: JS212 + JS207 Cohort 5: JS212 + Toripalimab
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age 18 to 75 years, male or female.
- •Histologically confirmed metastatic or unresectable clear cell renal cell carcinoma (RCC); histologically or cytologically confirmed metastatic or unresectable castration-resistant prostate cancer (CRPC); histologically or cytologically confirmed locally advanced or metastatic urothelial carcinoma (UC); histologically confirmed unresectable Stage III or IV melanoma.
- •For RCC: disease progression following prior anti-angiogenic targeted therapy and PD-(L)1 inhibitor therapy; for CRPC: disease progression following prior abiraterone or novel androgen receptor (AR) inhibitor therapy; for UC: disease progression following prior PD-(L)1 inhibitor and platinum-based chemotherapy or PD-(L)1 inhibitor and ADC drugs; for melanoma: disease progression following prior chemotherapy and/or PD-(L)1 inhibitor therapy.
- •At least one measurable lesion per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1).
- •Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or
- •Life expectancy ≥ 12 weeks.
- •Adequate organ function.
- •Male and female subjects of reproductive potential must agree to use highly effective contraception during the study and avoid conception; women of childbearing potential (WOCBP) must have a negative serum pregnancy test within 7 days prior to the first dose and must not be breastfeeding.
- •CRPC subjects must be on continuous luteinizing hormone-releasing hormone agonist (LHRHa) therapy or have undergone bilateral orchiectomy; subjects without bilateral orchiectomy must plan to maintain effective LHRHa therapy throughout the study; castrate levels of testosterone at screening; metastatic disease confirmed by CT/MRI or radionuclide bone scan.
- •Subjects voluntarily participate in the study and have signed the informed consent form.
排除标准
- •Major surgery, radiotherapy, chemotherapy, immunotherapy or other anti-tumor therapy, or other investigational agents administered prior to the first study dose.
- •Toxicity from prior anti-tumor therapy has not recovered to ≤ Grade 1 per CTCAE v6.0 or to the level specified in the inclusion/exclusion criteria.
- •Presence of active central nervous system (CNS) metastases.
- •Presence of clinically significant pleural effusion, ascites, or pericardial effusion requiring repeated intervention.
- •Uncontrolled hypertension despite medical therapy, or history of hypertensive crisis or hypertensive encephalopathy.
- •Severe cardiovascular or cerebrovascular disease.
- •History of interstitial lung disease (ILD)/non-infectious pneumonitis requiring corticosteroid therapy.
- •Severe bone injury due to tumor bone metastasis as judged by the investigator.
- •Severe infection (CTCAE v6.0 > Grade 2) within 28 days prior to the first study dose.
- •Active tuberculosis, hepatitis B, or hepatitis C infection.
- •History of immunodeficiency, or known history of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation.
- •History of another primary malignancy, except those with curative treatment and no known active disease for >5 years and low potential risk of recurrence.
- •Known hypersensitivity or severe allergic reaction to the study treatment, any of its components, or excipients.
- •Presence of any other condition that may result in premature discontinuation from the study.
- •Diagnosis of any other malignancy within 5 years.
- •Subjects participating in Cohorts 1, 3, 4, and 5:Prior treatment with an ADC targeting EGFR and/or HER3, or prior treatment with an ADC utilizing a topoisomerase I inhibitor as the payload；
- •Subjects participating in Cohorts 2, 3, 4, and 5: Administration of any live or live-attenuated vaccine within 28 days prior to the first dose, or anticipated need for such vaccination during the study.Use of systemic corticosteroids or other immunosuppressive agents for ≥7 consecutive days within 14 days prior to the first dose.Active autoimmune disease requiring systemic therapy within 2 years prior to the first dose.Development of a drug-related adverse event leading to permanent discontinuation of prior anti-PD-(L)1 antibody therapy.
- •Subjects participating in Cohorts 4:Imaging in the screening period demonstrates tumor encasement of major blood vessels, significant necrosis, or cavitation that, in the investigator's opinion, may confer a bleeding risk. Clinically significant hemoptysis or tumor bleeding of any cause within 28 days prior to the first dose.Gastrointestinal perforation, fistula, or intra-abdominal abscess within 6 months prior to enrollment, or current high risk of hollow organ perforation/fistula formation as judged by the investigator.History of gastrointestinal bleeding within 6 months prior to enrollment, or documented gastrointestinal bleeding tendency.Severe, non-healing or dehiscent wound, active ulcer, or untreated fracture.Significant bleeding diathesis or severe coagulopathy.Use of antiplatelet therapy or therapeutic anticoagulation within 14 days prior to the first dose.Development of a drug-related adverse event leading to permanent discontinuation of prior bevacizumab or similar agent therapy.
研究组 & 干预措施
Arm 5: JS212 in Combination with Toripalimab
Experimental
干预措施: Toripalimab (Drug)
Arm 1: JS212 Monotherapy
Experimental
干预措施: JS212 for Injection (Drug)
Arm 2: JS213 Monotherapy
Experimental
干预措施: JS213 for Injection (Drug)
Arm 3: JS212 in Combination with JS213
Experimental
干预措施: JS212 for Injection (Drug)
Arm 3: JS212 in Combination with JS213
Experimental
干预措施: JS213 for Injection (Drug)
Arm 4: JS212 in Combination with JS207
Experimental
干预措施: JS212 for Injection (Drug)
Arm 4: JS212 in Combination with JS207
Experimental
干预措施: JS207 for Injection (Drug)
Arm 5: JS212 in Combination with Toripalimab
Experimental
干预措施: JS212 for Injection (Drug)
结局指标
主要结局
ORR
时间窗: up to 6 years
Objective response rate(ORR), assessed by investigator ( per RECIST v1.1).
次要结局
- PFS(up to 6 years)
- DoR(up to 6 years)
- DCR(up to 6 years)
- OS(up to 6 years)
- Safety (AE)(up to 6 years)
- Laboratory test indicators(up to 6 years)
- dose-limiting toxicity（DLT）(up to 6 years)
研究者
研究点 (1)
Loading locations...
相似试验
尚未招募
2 期
A Phase II Clinical Study to Evaluate the Safety, Efficacy, Pharmacokinetics/Pharmacodynamics of JSKN033 in Patients With Advanced Non-Small Cell Lung CancerNCT07283198Jiangsu Alphamab Biopharmaceuticals Co., Ltd160
尚未招募
1 期
A Study of BL-M24D1 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumors and Other Solid TumorsNCT07279428Sichuan Baili Pharmaceutical Co., Ltd.33
招募中
1 期
A Study of HS-10566 in Patients With High-risk Non-muscle-invasive Bladder Cancer Who Are Ineligible for or Refuse Radical CystectomyNCT07468851Jiangsu Hansoh Pharmaceutical Co., Ltd.180
招募中
1 期
MRG006A Combination Therapy for Advanced Hepatocellular Carcinoma (Phase I/II)Hepatocellular CarcinomaNCT07479485Lepu Biopharma Co., Ltd.160
Enrolling By Invitation
1 期
Propranolol With Tislelizumab Plus GC in Neoadjuvant Bladder UCBladder Urothelial CarcinomaLymph Node MetastasisNCT07353294Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University12